WallStSmart

Meihua International Medical Technologies Co Ltd (MHUA)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 74239% more annual revenue ($66.57B vs $89.55M). MHUA leads profitability with a 10.3% profit margin vs 4.8%. MHUA trades at a lower P/E of 0.3x. MRK earns a higher WallStSmart Score of 36/100 (F).

MHUA

Avoid

34

out of 100

Grade: F

Growth: 2.0Profit: 6.0Value: 6.7Quality: 8.5
Piotroski: 2/9Altman Z: 5.83

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MHUA.

MRKSignificantly Overvalued (-77.2%)

Margin of Safety

-77.2%

Fair Value

$83.04

Current Price

$146.87

$63.83 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MHUA4 strengths · Avg: 10.0/10
P/E RatioValuation
0.3x10/10

Attractively priced relative to earnings

Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.8310/10

Safe zone — low bankruptcy risk

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

MHUA4 concerns · Avg: 2.5/10
Market CapQuality
$425.43M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-16.2%2/10

Revenue declined 16.2%

EPS GrowthGrowth
-42.0%2/10

Earnings declined 42.0%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.6x4/10

Trading at 8.6x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : MHUA

The strongest argument for MHUA centers on P/E Ratio, Price/Book, Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : MHUA

The primary concerns for MHUA are Market Cap, Piotroski F-Score, Revenue Growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

MHUA profiles as a declining stock while MRK is a value play — different risk/reward profiles.

MHUA carries more volatility with a beta of 0.75 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Meihua International Medical Technologies Co Ltd

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Meihua International Medical Technologies Co., Ltd. is engaged in the manufacturing and marketing of medical consumables in the People's Republic of China.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?